Oral Degraders with Biologics-like Efficacy Can Transform Immunology
Existing Therapies Address 10% or Less of Diagnosed Patients1



            STAT6                                          IRF5                                        IRAK4
    TRANSCRIPTION FACTOR                         TRANSCRIPTION FACTOR                           SCAFFOLDING KINASE



Key Indications: AD, Asthma, COPD,          Key Indications: SLE, RA, UC, CD,             Key Indications2: HS, AD, Asthma,
EoE, CRSwNP, CSU, PN, BP                    Sjögrens, SSc, DM                             COPD, RA, SLE, UC, CD

                                                                      Systemic Advanced
                        Systemic Advanced                               Therapies: 7%                              Systemic Advanced
                          Therapies: 1%                                                                              Therapies: 3%
                                                  >10M Patients                                >140M Patients
   >140M Patients                                                                            (∼ 54% mod./severe)
  (∼ 54% mod./severe)                           (∼ 65% mod./severe)
                             >$20B1                                        >$45B1                                       >$55B1




                                                                                                                                 9
